Sponsors

About

More than a century since pathological protein aggregates were first identified in the brain of patients with neurodegenerative diseases (NDDs) and we still do not have effective therapies to treat or slow the progression of NDDs or diagnostics for early detection and monitoring disease progression. Recent findings are challenging traditional views about the composition, ultrastructural properties, and heterogeneity of protein pathologies in the brain, their mechanisms of formation and their and how we investigate and model pathological aggregation processes associated with NDs in the laboratory today. The primary objective of this symposium is to gather leading scientists from different disciplines to discuss and debate the latest findings, share the latest advances from their group, and brainstorm collectively about how to leverage and integrate the latest conceptual and technical advances in imaging and image analyses to address current knowledge and technological gaps and advance translational research in NDDs.

Goals

  • Reassess our understanding of the human pathology in neurodegenerative diseases (NDDs) and to what extent their diversity and complexity are accounted for in our mechanistic models and translational approaches.
  • Put the spotlight on knowledge gaps, conceptual and technical challenges slowing our progress towards effective therapies and diagnostics.
  • Increase awareness in the field about emerging concepts and technologies and discuss how to facilitate their integration into ongoing research aimed at elucidating the mechanisms underpinning NDDs and to advance translation research in NDDs.
  • Learning from success stories in other fields

This is a discussion-oriented meeting, and the format of all the sessions is designed to allow for ample times for stimulating discussions focused on understanding the current state of the art, knowledge gaps, and unanswered questions in the field. The ultimate goal is to achieve some convergence on defining the research priorities and opportunities that would enable us to translate our understanding of brain pathology in proteinopathies to accelerate ongoing and future efforts aimed at developing effective therapies for the treatment NDDs.

Topics

  • Revisiting the human pathology at the molecular and structural levels
  • Imaging Biomarkers for neurodegenerative diseases with an emphasis on PET Tracers
  • Integrative approaches to investigating phase separation and aggregation in cellular and animal model systems
  • New and emerging imaging and structure determination technologies (XRD, FEL, LiP-MS, in-cell NMR, Cryo-EM)
  • Peripheral pathology as a window to brain pathology in NDDs.

For each theme, we will address

State of the art

The current state of the art and key outstanding questions that, if answered, could transform the field

Challenges

Current conceptual and technical challenges

Artificial intelligence

How the latest advances in AI, computational approaches, and image analysis could be applied to address these challenges

Scaling technology

How new technological advances could be scaled to support translational research and drug discovery

Posters

Posters – Names only

Posters – Names & portraits

Organizing comittee

Hilal A. Lashuel

Associate professor, Swiss Federal Institute of Technology Lausanne (EPFL)

Read more
Hilal A. Lashuel
Roland Riek

ETH Zurich

Read more
Roland Riek
Jamie Eberling

THE MICHAEL J. FOX FOUNDATION FOR PARKINSON’S RESEARCH

Read more
Jamie Eberling
Aleksandra Radenovic

Swiss Federal Institute of Technology Lausanne (EPFL)

Read more
Aleksandra Radenovic
Benjamin Stecher

Rune Labs, San Francisco

Read more
Benjamin Stecher
Henning Stahlberg

Laboratory of Biological Electron Microscopy, IPHYS, SB, EPFL, and Dep. Fundamental Microbiology, Faculty of Biology and Medicine, Uni Lausanne, Lausanne, Switzerland

Read more
Henning Stahlberg
Paola Picotti

ETH Zurich

Read more
Paola Picotti
Laurène Donati

Swiss Federal Institute of Technology Lausanne (EPFL)

Read more
Laurène Donati
Michaël Unser

Swiss Federal Institute of Technology Lausanne (EPFL)

Read more
Michaël Unser

Speakers/Panellists

Hilal A. Lashuel

Associate professor, Swiss Federal Institute of Technology Lausanne (EPFL)

Read more
Hilal A. Lashuel
Aleksandra Radenovic

Swiss Federal Institute of Technology Lausanne (EPFL)

Read more
Aleksandra Radenovic
Wilma van de Berg

Amsterdam UMC

Read more
Wilma van de Berg
Ignacio Muñoz-Sanjuán

CHDI Foundation

Read more
Ignacio Muñoz-Sanjuán
Judith Steen

Boston Children's Hospital / Harvard Medical School

Read more
Judith Steen
Sjoerd Finnema

Abbvie Inc

Read more
Sjoerd Finnema
Amanda Lewis

Swiss Federal Institute of Technology Lausanne (EPFL)

Read more
Amanda Lewis
Abid Oueslati

Université Laval, Department of Molecular Medicine & CHU de Quebec Research Center, Axe Neuroscience

Read more
Abid Oueslati
Paola Picotti

ETH Zurich

Read more
Paola Picotti
Benjamin Stecher

Rune Labs, San Francisco

Read more
Benjamin Stecher
Sjors Scheres

Cambridge Biomedical Campus

Read more
Sjors Scheres
Sara Elfarrash

Mansoura University

Read more
Sara Elfarrash
Melissa Murray

Mayo Clinic, Jacksonville

Read more
Melissa Murray
Jamie Eberling

THE MICHAEL J. FOX FOUNDATION FOR PARKINSON’S RESEARCH

Read more
Jamie Eberling
Anne-Laure Mahul

Swiss Federal Institute of Technology Lausanne (EPFL)

Read more
Anne-Laure Mahul
Malvindar Singh-Bains

Centre for Brain Research | University of Auckland | Faculty of Medical and Health Sciences

Read more
Malvindar Singh-Bains
Roland Riek

ETH Zurich

Read more
Roland Riek
Laura Parkkinen

University of Oxford

Read more
Laura Parkkinen
Celia Dominguez

CHDI Foundation

Read more
Celia Dominguez
Bradford Navia

Aprinoia therapeutics LLC Massachusetts

Read more
Bradford Navia
David Eisenberg

University of California UCLA

Read more
David Eisenberg
Senthil Kumar Thangaraj

Swiss Federal Institute of Technology Lausanne (EPFL)

Read more
Senthil Kumar Thangaraj
Efthymia (Effie) Vokali

AC Immune

Read more
Efthymia (Effie) Vokali
Ozgun Gokce

Institute for Stroke and Dementia Research
Ludwig Maximilians-University of Munich (LMU), Germany

Read more
Ozgun Gokce
Henning Stahlberg

Laboratory of Biological Electron Microscopy, IPHYS, SB, EPFL, and Dep. Fundamental Microbiology, Faculty of Biology and Medicine, Uni Lausanne, Lausanne, Switzerland

Read more
Henning Stahlberg
Jens Christian Schwamborn

University of Luxembourg

Read more
Jens Christian Schwamborn
Glenda Halliday

The University of Sydney

Read more
Glenda Halliday
Steve Finkbeiner

Gladstone Institutes / University of California, San Francisco

Read more
Steve Finkbeiner
Magdalini Polymenidou

University of Zurich

Read more
Magdalini Polymenidou
Gioele La Manno

Swiss Federal Institute of Technology Lausanne (EPFL)

Read more
Gioele La Manno
Adriano Aguzzi

Prof. Dr. med.
Director, Institute of Neuropathology
Director, University Center for Laboratory Medicine and Pathology

Read more
Adriano Aguzzi
Markus Britschgi

Roche Pharma Research & Early Development, Roche Innovation Center Basel

Read more
Markus Britschgi

Event Schedule

Benjamin Stecher, Canada

08:15 – 08:30

Hilal Lashuel

Glenda Halliday, The University of Sydney, Australia

09:40 – 10:00

Steve Finkbeiner, Gladstone Institutes / University of California, San Francisco, USA

11:45 – 12:10

Steve Finkbeiner, Gladstone Institutes / University of California, San Francisco, USA

12:10 – 13:00

Hilal Lashuel and Adriano Aguzzi

13:00 – 14:00

Hilal Lashuel and Adriano Aguzzi

New tools and approaches to capture the molecular diversity of pathological aggregates and elucidate their role in disease pathogenesis

Malvindar Singh-bain, University of Auckland, New Zealand

15:20 – 15:40

Chairs: Wilma Van de Berg and Ignacio Muñoz-Sanjuán

15:40 – 16:00

Progress towards developing PET imaging tracers

Ignacio Muñoz-Sanjuán, CHDI Foundation, USA

Bradford Navia, APRINOIA THERAPEUTICS LLC, USA

17:35 -18:00

Chairs: Celia Dominguez, CHDI Foundation, USA
Jamie Eberling, Michael J Fox Foundation, USA

09:00 – 09:40

Structure-based discovery of small-molecules that disassemble tau fibrils of Alzheimer's disease.

David Eisenberg, University of California UCLA, USA

Sjors Scheres, Cambridge Biomedical Campus, United Kingdom

10:50 – 11:00

Roland Riek, ETH Zurich, Switzerland

12:10 – 12:40

Sjoerd Finnema and Laura Parkkinen

12:40 -14:00

Magdalini Polymenidou, University of Zurich, Switzerland

Jens Christian Schwamborn, University of Luxembourg, Luxembourg

16:10 -16:20

System-based approaches to deciphering the genetic, molecular, and structural determinants of pathology formation in neurodegenerative diseases

Chair: Steve Finkbeiner

Judith Steen, Boston Children's Hospital / Harvard Medical School, USA

16:45 – 17:10

Paola Picotti, ETH Zurich, Switzerland

Registration fees

Registration are not open.

PhD students & Post-docs
150.-CHF
Included:
Access to lecture room
Coffee breaks
Lunches
Foundations / Faculty / Professors
200.-CHF
Included:
Access to lecture room
Coffee breaks
Lunches
Industry participants
350.-CHF
Included:
Access to lecture room
Coffee breaks
Lunches

Abstract submission

Abstract submissions deadline : August 15, 2022

Please submit abstracts by emailing : marie.rodriguez@epfl.ch with subject : “Latsis Symposium 31.08.2022 abstract submission” and indicate whether you wish that your abstract should be considered for a short talk.

If your contribution has been accepted for poster, please prepare a poster size A0 : 119 × 84 cm (height x width) // Vertical. The posters do not have to be sent in advance; please take yours along on the first day of the conference, where they can be put up before the welcome address.

Abstract preparation and format

Please submit a title of no more than 20 words, and keep your abstract to no more than 300 words. Together with this, please also submit affiliations of all authors, sticking to the following format.

Adams, A.(1), Smith, S.(1,2), & Jones, J.(2),
1 Center for Brain Science, Harvard University, USA
2 Brain Mind Institute, EPFL, Switzerland.
Corresponding author: a.adams@harvard.edu

Frequently Asked Questions

Check out the FAQs to find the answers to common questions. Can't find your question answered here? Contact us.

When will the conference take place ?

The conference will take place from the 31st of August until the 2nd of September 2022.

Where will the conference take place ?

The conference will take place in the SG1 room located on the EPFL campus.

Accommodation

Recommended options for accommodation include the Starling Hotel and the Swisstech Hotel for the proximity to the conference venue.

The Starling Hotel

You can directly register at the Starling hotel using the link below.

Swisstech Hotel

To register to the Swisstech Hotel you need to send an email to: sth@epfl.ch.

To facilitate the registration please put “LATSIS2022 STH Registration” as object of your email and include:

• First name and last name

• Dates of your registration

• Number of people

• Include or not the breakfast

• Code: LATSIS2022

All train timetables are available here:

Arriving by plane

From Geneve airport (Cointrin) to Lausanne

The journey to Lausanne takes about 45 minutes. There are 3 departures per hour. Most connections are direct from the “Geneve aéroport” bus station to Lausanne.

You will find the timetables at the above address.

From Zurich airport (Kloten) to Lausanne

The journey to Lausanne takes about 2½ hours. There are 2 departures per hour. Some trains have a connection in Bern or  Zürich Hauptbahnhof (Zürich HB). Follow the link above and type as your departure location: “Zürich Flughafen”.

From Bâle airport (EuroAirport) to Lausanne

There isn’t any train station at the airport. You’ll have to take a shuttle to the central railway station (Basel SBB) which takes about 20 minutes. The journey to Lausanne takes about 2½ hours. There are 2 departures per hour. There will be a connection weather in Berne or Bienne. Follow the link above and type your departure location: “Basel Airport”.

Arriving by train

From Paris to Lausanne

4 TGV per day connect Paris-Gare de Lyon to Lausanne. The journey is direct and takes about 4 hours.

From Lyon to Lausanne

The journey from Lyon-Part-Dieu” to Lausanne takes 2½ heures. There is a train every 2 hours. Please note that there is a connection in Genève.

From Milan to Lausanne

From Milan central train station, the journey takes 4 hours (3 hours with the cisalpin). There is a departure every 2 hours. Usually there is no connection.

Getting to the conference

Due to severely restricted parking availabilities on EPFL grounds, we strongly recommend using taxi or public transportation to get there. You can reach EPFL using metro line M1 from Lausanne or Renens, bus lines 701 from Morges and 31 from Ecublens/Renens/Prilly.

If driving is the only option, you can purchase parking tickets for the visitor parking (white places) at the parking meters (2 CHF per hour from 7am to 5pm).

Public transportation

Please buy a ticket for the needed number of zones (between 3 and 4CHF)

From Lausanne (20 to 30 minutes)

From Lausanne, take the M2 from the CFF train station (next to the Mc Donald). Go down at the Flon stop and take the M1 in direction of Renens and go down at the EPFL stop. Then walk across the EPFL campus to the SG building.

From Renens (20mn)

Take the bus n°31 in direction of “Venoge Sud” go down at the stop “Paqueret”, don’t forget to press the red button in the bus to ask the bus to stop. Then walk to the SV building.

Or take the metro m1 in direction of Lausanne Flon, go down at the EPFL stop. Then walk across the EPFL to the SG building.

By Uber

There are Uber drivers in Lausanne. Please download the app on your phone to book a ride.

By taxi

Find below the link to the website of Lausanne taxis.

Meals

EPFL Campus offers a variety of restaurants open to the public.

Will I be able to connect to the internet ?

Wireless internet access will be granted to the symposium participants:

freeWifi-Epfl

    Username: TBD

    Password: TBD

Event location

Here, you will find directions to the conference venue.

Contact us

marie.rodriguez@epfl.ch